These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24405856)

  • 1. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
    Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
    Dubreuil P; Letard S; Ciufolini M; Gros L; Humbert M; Castéran N; Borge L; Hajem B; Lermet A; Sippl W; Voisset E; Arock M; Auclair C; Leventhal PS; Mansfield CD; Moussy A; Hermine O
    PLoS One; 2009 Sep; 4(9):e7258. PubMed ID: 19789626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
    Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
    BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Masitinib for the treatment of mild to moderate Alzheimer's disease.
    Folch J; Petrov D; Ettcheto M; Pedrós I; Abad S; Beas-Zarate C; Lazarowski A; Marin M; Olloquequi J; Auladell C; Camins A
    Expert Rev Neurother; 2015 Jun; 15(6):587-96. PubMed ID: 25961655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
    Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
    Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I
    Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of masitinib for treating systemic mastocytosis.
    Laforgia M; Marech I; Nardulli P; Calabrò C; Gadaleta CD; Ranieri G
    Expert Opin Pharmacother; 2019 Sep; 20(13):1539-1550. PubMed ID: 31381378
    [No Abstract]   [Full Text] [Related]  

  • 9. Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro.
    Rathore K; Alexander M; Cekanova M
    Transl Res; 2014 Aug; 164(2):158-68. PubMed ID: 24631063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo model for mastocytosis: A comparative review.
    Ranieri G; Marech I; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Rizzo A; Gadaleta CD; Introna M; Patruno R; Sciorsci RL
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):159-69. PubMed ID: 25465741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
    Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
    J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of masitinib mesylate in healthy cats.
    Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
    J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masitinib is safe and effective for the treatment of canine mast cell tumors.
    Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
    J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
    Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
    J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
    Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
    BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
    Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
    Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
    Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.